The Chinese biotech put the idea to the test in a phase 2 trial of a subcutaneous depot formulation of its GLP-1 receptor agonist ASC30. U.S. investigators randomized 65 people with obesity or who ...
Bioavailability data recently obtained from Phase 1 study with a stable crystal form of neflamapimod manufactured using a new, controlled ...
MVID has a lethal natural history requiring life-sustaining parenteral support (PS), which includes total parenteral ...
Researchers at the George Washington University School of Medicine and Health Sciences in partnership with Baylor College of Medicine report encouraging results from a phase 2 clinical trial ...
Touya, who most recently served as Aptar Pharma President, will succeed Stephan Tanda, who has served as President and CEO of the firm since 2017 ...
Q4 2025 earnings call: nimacimab + semaglutide data, higher-dose expansion, Halozyme SC plans, 2026 catalysts—read now.
The Phase 2b study to assess enobosarm’s ability to preserve lean mass, physical function, and bone as well as burn more fat to produce ...
In a call hosted recently, Nasus Pharma (NYSE:NSRX) presented strong positive topline results from its Phase 2 clinical study ...
Ralinepag reduced the risk of clinical worsening in patients with pulmonary arterial hypertension by 55%, according to recent study results.
SCYNEXIS, Inc. (NASDAQ:SCYX) is among the 11 Fastest Growing Penny Stocks to Buy Right Now. On February 26, 2026, SCYNEXIS, Inc. (NASDAQ:SCYX) announced that the first participants had been dosed in a ...
SHINKEI THERAPEUTICS RECEIVES FDA CLEARANCE TO PROCEED WITH PHASE 1 CLINICAL TRIAL FOR MR-101 AND COMPLETES PHASE 2 ...
LTR Pharma recently announced the dosing of the first patients in the Phase II study of SPONTAN ®, which is evaluating the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results